A Member of the Cancer Information Network
Cancer Information by State:
  arrow Patient Home   arrow Professional Home   arrow Newsletters   arrow Feedback Survey  
Main Menu
Quick Links
Information by Disease
Cancer News
Conference Coverage
Oncology Stocks
AZN$44.350.36 (0.82%)
NVS$54.7-0.04 (-0.07%)
SNY$38.04-0.15 (-0.39%)
GSK$37.82-0.02 (-0.05%)
click here
Bone Cancer Information Center
Folder Conference Coverage

 
People Current Topics

Limb Salvage Management of Pathologic Fractures of Primary Malignant Bone Tumors

News Latest Bone Cancer News

Denosumab Effective for Giant Cell Tumor of the Bone (2/16/2010)
Researchers involved in an international Phase II clinical trial have reported that denosumab produced responses in the majority of patients with giant cell tumor of the bone. The details of this study were published early online in Lancet Oncology on February 10, 2010.[1] These results were previously presented in preliminary form at the 2009 annual meeting of the American Society of Clinical Oncology in Orlando, Florida, on June 1.

Denosumab Produces Promising Results Against Giant Cell Tumor of the Bone (6/10/2009)
Researchers involved in an international Phase II clinical trial have reported that 86% of patients with giant cell tumor of the bone responded to treatment with denosumab. These results were presented at the 2009 annual meeting of the American Society of Clinical Oncology in Orlando, Florida, on June 1.

Immunostimulant MTP Improves Survival in Pediatric Osteosarcoma (3/5/2008)
Researchers affiliated with the Children’s Oncology Group have shown that the addition of muramyl tripeptide (MTP) to chemotherapy improves survival in patients with osteosarcoma. The details of this study appeared in the February 1, 2008 issue of the Journal of Clinical Oncology.

Not Approvable Letter for Mifamurtide (9/19/2007)
IDM Pharma, Inc. has received a not approvable letter from the United States Food and Drug Administration (FDA) for their investigational drug mifamurtide (L-MTP-PE) – formerly Junovan – for the treatment of osteosarcoma.  

Neoadjuvant Chemotherapy Effective for Older Patients with Osteosarcoma (8/6/2007)
Researchers from Italy have reported that neoadjuvant chemotherapy improves prognosis and reduces amputations in patients over 40 years of age with localized osteosarcoma of the extremity. The details of this study appeared in the June, 2007 issue of Acta Orthopedica.

More Bone Cancer News »

Bone Cancer Drug Pipeline

What's in the pipeline for Bone Cancer.
Newsletters

Register in our member center today to receive a monthly newsletter with clinical news, conference coverage, and current topic updates.
 
Information by Cancer Type

 Supportive Care Centers

 Physician Resources




© 1998-2010 CancerConsultants.com  All Rights Reserved.